ONCY Share Price Performance
US$0
-0.82 (-100.00%)
Price US$0
Share Pricen/a
Oncolytics Biotech Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ONCY Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Oncolytics Biotech Inc. Key Details
About ONCY
- Founded
- 1998
- Employees
- 28
- CEO
- WebsiteView website
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
